GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Black Bird Biotech Inc (OTCPK:BBBT) » Definitions » Debt-to-EBITDA

Black Bird Biotech (Black Bird Biotech) Debt-to-EBITDA : 4.45 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Black Bird Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Black Bird Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.75 Mil. Black Bird Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Black Bird Biotech's annualized EBITDA for the quarter that ended in Sep. 2023 was $0.17 Mil. Black Bird Biotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 4.45.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Black Bird Biotech's Debt-to-EBITDA or its related term are showing as below:

BBBT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -29.92   Med: -6.56   Max: -0.04
Current: -29.92

During the past 13 years, the highest Debt-to-EBITDA Ratio of Black Bird Biotech was -0.04. The lowest was -29.92. And the median was -6.56.

BBBT's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BBBT: -29.92

Black Bird Biotech Debt-to-EBITDA Historical Data

The historical data trend for Black Bird Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Bird Biotech Debt-to-EBITDA Chart

Black Bird Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.43 -10.94 -0.07 -0.04 -0.56

Black Bird Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -1.34 2.36 -10.13 4.45

Competitive Comparison of Black Bird Biotech's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Black Bird Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Black Bird Biotech's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Black Bird Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Black Bird Biotech's Debt-to-EBITDA falls into.



Black Bird Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Black Bird Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.67 + 0) / -1.199
=-0.56

Black Bird Biotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.745 + 0.003) / 0.168
=4.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Black Bird Biotech  (OTCPK:BBBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Black Bird Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Black Bird Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Black Bird Biotech (Black Bird Biotech) Business Description

Traded in Other Exchanges
N/A
Address
11961 Hilltop Road, Suite 22, Argyle, TX, USA, 76226
Black Bird Biotech Inc is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. In addition, it is the distributor in the U. S. and Canada for MiteXstream, an EPA-registered plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Its products include MiteXstream Biopesticide, Grizzly Creek Naturals, and Black Bird American Hemp.
Executives
Jeffrey A Collins director, 10 percent owner, officer: President 302 WASHINGTON ST., #513, SAN DIEGO CA 92103
Robert Edward Shea director, 10 percent owner, officer: President, CEO, CFO, CAO 40 WARREN STREET, 3RD FLOOR, CHARLESTOWN MA 02129
John James Sutherland director, 10 percent owner, officer: President, CEO, CFO & CAO C/O SUITE 810 - 675 WEST HASTINGS STREET, VANCOUVER A1 V6B 1N2

Black Bird Biotech (Black Bird Biotech) Headlines

From GuruFocus